What is the long-term trend for CytomX Therapeutics's indefinite-lived intangible assets, gross?

Over 5 years (2020 to 2025), CytomX Therapeutics's indefinite-lived intangible assets, gross has grown at a -17.8% compound annual growth rate (CAGR), from $1.17M to $438K.

CytomX Therapeutics CTMX Indefinite-Lived Intangible Assets, Gross

Indefinite-Lived Intangible Assets, Gross at other companies

PfizerPFE

——

Perspective TherapeuticsCATX

——

Zevra Therapeutics, Inc.ZVRA

——

Fulgent Genetics, Inc.FLGT

——

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's indefinite-lived intangible assets, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's indefinite-lived intangible assets, gross?: CytomX Therapeutics (CTMX) reported indefinite-lived intangible assets, gross of $401K in Q1 2026.
How has CytomX Therapeutics's indefinite-lived intangible assets, gross changed year-over-year?: CytomX Therapeutics's indefinite-lived intangible assets, gross decreased by 26.7% year-over-year, from $547K to $401K.
What is the long-term trend for CytomX Therapeutics's indefinite-lived intangible assets, gross?: Over 5 years (2020 to 2025), CytomX Therapeutics's indefinite-lived intangible assets, gross has grown at a -17.8% compound annual growth rate (CAGR), from $1.17M to $438K.